Daidzein alleviates CCl4- and BDL-induced liver fibrosis via suppressing the integrin alphaVbeta1/YAP signaling

and BDL. It inhibited the activation of HSCs and reduced liver fibrosis by targeting the integrin/YAP signaling pathway. These findings suggested that DAI may serve as a potential candidate for anti-hepatic fibrosis chemical drugs.